Search hospitals > Iowa > Clive
Iowa Digestive disease center
Claim this profileClive, Iowa 50325
Conducts research for Crohn's Disease
Conducts research for Ulcerative Colitis
Conducts research for Inflammatory Bowel Disease
Conducts research for Ulcer
Conducts research for Liver Cirrhosis
34 reported clinical trials
1 medical researcher
Summary
Iowa Digestive disease center is a medical facility located in Clive, Iowa. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease, Ulcer, Liver Cirrhosis and other specialties. Iowa Digestive disease center is involved with conducting 34 clinical trials across 33 conditions. There are 1 research doctors associated with this hospital, such as Bernard Leman, MD.Top PIs
Clinical Trials running at Iowa Digestive disease center
Ulcerative Colitis
Inflammatory Bowel Disease
Ulcer
Esophagitis
Eosinophilic Esophagitis
Crohn's Disease
Liver Cirrhosis
Nonalcoholic Steatohepatitis
MK-7240
for Ulcerative Colitis
This trial is testing tulisokibart, a new medication, to see if it can help people with moderately to severely active ulcerative colitis. The goal is to determine if tulisokibart can reduce inflammation and heal sores in the colon, leading to fewer symptoms. The study will compare different doses of tulisokibart over several months.
Recruiting1 award Phase 3
ABX464 Maintenance Therapy
for Ulcerative Colitis
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106. All eligible subjects who have completed either one of the induction studies above mentioned, will be given the opportunity to take part in the present ABX464-107 maintenance study and will be randomized to either a double blind, placebo-controlled part (Part #1) or allocated to ABX464 50mg or 25mg open label treatment arms (Part #2) depending on their clinical response at the end of induction. This study consists of a 44-week treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit.
Recruiting1 award Phase 3
ABX464
for Ulcerative Colitis
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].
Recruiting1 award Phase 36 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Iowa Digestive disease center?
Iowa Digestive disease center is a medical facility located in Clive, Iowa. This center is recognized for care of Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease, Ulcer, Liver Cirrhosis and other specialties. Iowa Digestive disease center is involved with conducting 34 clinical trials across 33 conditions. There are 1 research doctors associated with this hospital, such as Bernard Leman, MD.